Small Molecule Protease Inhibitors as Model Peptidomimetics.

Area of Science:

• Biochemistry and Molecular Biology
• Enzymology
• Drug Discovery

Background:

• Proteases are vital enzymes regulating physiological processes, with dysregulation linked to diseases like cancer and neurodegenerative disorders.
• Protease inhibitors offer therapeutic potential by modulating enzyme activity, complementing control via enzyme concentration.
• Small molecule protease inhibitors are developed using substrate-based design and iterative optimization for improved drug-like properties.

Purpose of the Study:

• To review the design process of protease inhibitors, from initial substrate-based approaches to optimized second-generation drugs.
• To exemplify the inhibitor design process through successful discovery stories of inhibitors targeting diverse protease classes.
• To examine challenges in novel protease inhibitor design and their market relevance.

Main Methods:

• Review of literature on protease inhibitor design strategies.
• Analysis of case studies involving inhibitors for angiotensin converting enzyme, HIV protease, thrombin, and proteasome.
• Examination of drug development challenges and market impact.

Main Results:

• Successful design of protease inhibitors involves iterative optimization, moving from first-generation substrate mimics to second-generation drugs with improved pharmacokinetic profiles.
• Case studies demonstrate effective inhibitor development for metalloproteases, aspartate proteases, serine proteases, and threonine proteases.
• Despite successes, challenges remain in designing novel protease inhibitors, yet they hold significant therapeutic and market value.

Conclusions:

• Protease inhibitors represent a significant class of therapeutics, with rational design strategies enabling successful drug development.
• The iterative optimization of substrate-based inhibitors is key to achieving effective and safe therapeutic agents.
• Continued research into protease inhibitor design is essential for addressing unmet medical needs and expanding therapeutic options.